US2021115006A1PendingUtilityA1

Novel compositions and methods for cancer treatment

74
Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY INCPriority: Sep 10, 2007Filed: Oct 9, 2020Published: Apr 22, 2021
Est. expirySep 10, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Chiang Jia LiKeith MikuleYouzhi Li
A61P 35/04A61P 17/06C07D 333/74A61P 37/00A61P 17/12A61P 11/06A61P 37/06A61P 37/02A61P 25/28A61K 31/38A61P 25/02A61P 1/04A61K 31/343A61P 35/00C07D 307/92Y02A50/30A61P 25/00A61P 31/00A61P 9/10A61P 1/00A61P 7/00A61P 43/00A61P 37/08A61K 47/42A61P 17/02A61P 35/02A61P 19/02A61K 47/24A61P 29/00A61K 47/44A61P 9/00
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the composition and method of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating cancer in a human subject in need thereof comprising administering to said subject
 a therapeutically effective amount of synthetic 2-acetylnaphtho[2,3-b]furan-4,9-dione, and   a therapeutically effective amount of at least one agent chosen from bevacizumab, bortezomib, capecitabine, cetuximab, fluorouracil, imatinib, irinotecan, leucovorin, oxaliplatin, panitumumab, pemetrexed, temozolomide, cisplatin, paclitaxel, erlotinib, sunitinib, lapatinib, sorafenib, carboplatin, doxorubicin, docetaxel, gemcitabine, and etoposide,   wherein said cancer is pancreatic cancer or colorectal cancer,   wherein said cancer expresses activated STAT3.

Join the waitlist — get patent alerts

Track US2021115006A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.